$0.31
0.03% yesterday
Nasdaq, May 20, 10:06 pm CET
ISIN
US03835L1089
Symbol
APVO
Sector
Industry

Aptevo Therapeutics Inc Stock price

$0.31
-0.33 51.25% 1M
-10.42 97.11% 6M
-4.00 92.81% YTD
-27.22 98.87% 1Y
-7,407.09 100.00% 3Y
-9,556.05 100.00% 5Y
-182,335.69 100.00% 10Y
Nasdaq, Closing price Tue, May 20 2025
-0.00 0.03%
ISIN
US03835L1089
Symbol
APVO
Sector
Industry

Key metrics

Market capitalization $2.51m
Enterprise Value $4.79m
P/E (TTM) P/E ratio 0.00
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-24.10m
Free Cash Flow (TTM) Free Cash Flow $-23.71m
Cash position $2.14m
EPS (TTM) EPS $-88.45
Short interest 8.15%
Show more

Is Aptevo Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Aptevo Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Aptevo Therapeutics Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Aptevo Therapeutics Inc:

Buy
100%

Financial data from Aptevo Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs 0.22 0.22
56% 56%
-
- -
-
-
- Selling and Administrative Expenses 9.84 9.84
10% 10%
-
- Research and Development Expense 14 14
13% 13%
-
-24 -24
14% 14%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -24 -24
14% 14%
-
Net Profit -24 -24
12% 12%
-

In millions USD.

Don't miss a Thing! We will send you all news about Aptevo Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aptevo Therapeutics Inc Stock News

Neutral
Accesswire
6 days ago
9 of 10 frontline AML patients achieve remission with mipletamig + standard of care across two trials Mipletamig triplet combination continues to outperform standard doublet benchmark No cytokine release syndrome observed in the ongoing RAINIER trial: favorable safety profile supports role in frontline AML Cohort 2 enrollment is complete, and Cohort 3 is now enrolling SEATTLE, WA / ACCESS Newsw...
Neutral
Accesswire
13 days ago
As lead candidate mipletamig continues to outperform efficacy and safety benchmarks in AML trials, APVO711 exemplifies emerging innovation from Aptevo's proprietary ADAPTIR® platform In preclinical studies, APVO711 demonstrates dual anti-cancer functionality with broad solid tumor potential and developability SEATTLE, WASHINGTON / ACCESS Newswire / May 8, 2025 / Aptevo Therapeutics Inc. (Nasdaq...
Neutral
Accesswire
28 days ago
SEATTLE, WA / ACCESS Newswire / April 22, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, announced the closing of its previously announced offering of 2,324,000 shares of the Company's common stock ...
More Aptevo Therapeutics Inc News

Company Profile

Aptevo Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics to improve patients lives. Its pipeline includes APVO210, APVO436, ROR1 Candidate, and ALG.APV-527. The company was founded on February 22, 2016 and is headquartered in Seattle, WA.

Head office United States
CEO Marvin White
Employees 42
Founded 2016
Website www.aptevotherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today